A Review of Atypical Femoral Fractures From a Tertiary Care Teaching Hospital: An Alarming Trend?. Issue 4 (April 2016)

• Record Type: Journal Article
• Authors: Black, John-David; Kancherla, Vamsi K.; De Long, William G.
• Is Part Of: Journal of orthopaedic trauma. Volume 30:Issue 4(2016)
• Publication Date: 2016-04
• Subjects: bisphosphonate -- atypical femur fracture -- geriatric; Orthopedics -- Periodicals; Wounds and injuries -- Periodicals; Orthopedics -- Periodicals; Wounds and Injuries -- therapy -- Periodicals; Periodicals; 617.47044
• DOI: 10.1097/BOT.0000000000000539
• Languages: English
• ISSNs: 0890-5339

Abstract

Abstract : Objective: To evaluate the experience of a single tertiary care teaching hospital with the association between use of bisphosphonates and atypical femoral fractures, and to identify potential risk factors and chronologic incidence. Design: Retrospective review. Setting: Tertiary-care teaching hospital. Patients: Thirty-two patients with a total of 43 fractures met inclusion criteria. Intervention: Treatment for atypical femur fractures. Main Outcome Measurements: Radiographic assessments, duration of bisphosphonate therapy, prodromal symptoms, associated medications/comorbidities. Results: Thirty-one female patients and 1 male patient, with a total of 43 fractures, with an average age of 71.0 (47–92 years) ± 11.01 years at time of fracture, had an average duration of bisphosphonate therapy of 7.57 (1–12 years) ± 3.07 years. Prodromal thigh pain was reported in 20 of 43 fractures (46.5%). Eleven of the forty-three (25.5%) fractures occurred between 2001 and 2005. From 2006 to May 2011, however, 32/43 (74.5%) were reported. Beta-blockers, ACE/ARBs, and Statins (43.8%) were the most common concomitant medications, whereas Levothyroxine (21.8%), H-2 blockers (15.6%), and Glucocorticoids (12.5%) were less common. Conclusions: There is an increasing trend of atypical femur fractures in the current adult population. Bisphosphonate therapy beyond 7 years may place patients at increased risk. Level of Evidence: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.